Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma, Inc. (INZY)
:INZY
Holding INZY?
Track your performance easily
INZY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.32 - $7.80
Previous CloseN/A
Volume213.66K
Average Volume (3M)777.50K
Market Cap
$87.37M
Enterprise Value$246.12M
Total Cash (Recent Filing)$43.16M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.01
Next Earnings
Mar 20, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding64,240,200
10 Day Avg. Volume1,041,492
30 Day Avg. Volume777,504
Standard Deviation0.30
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap2.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.94
Forecast
1Y Price Target
$19.00Price Target Upside1297.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Inozyme Pharma News
PremiumCompany Announcements
Inozyme Pharma Advances with Promising Trial Results
PremiumCompany Announcements
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive interim results for the phase 1b ENERGY-1 trial in infants add to confidence in a positive pivotal readout.
Market OpportunityThere is encouragement by the market opportunity for INZ-701, given no approved therapies and prior data supporting its potential clinical benefit.
Regulatory DesignationsINZ-701 has orphan drug designation from the EMA and the FDA for the treatment of ENPP1 Deficiency, as well as FDA Fast Track designation and rare pediatric disease designation.
Bears Say
Development TimelineThe pivotal trial initiation in ABCC6 has been pushed back to early 2026.
Financial ConcernsThe stock could be under near-term pressure due to the relatively long development timelines for ABCC6 and the financing overhang to get to Ph3 ENPP1 data.
Regulatory And Data RisksCalciphylaxis specific data and regulatory alignment still need de-risking.
---
Ownership Overview
2.95% Insiders
17.21% Mutual Funds
60.08% Other Institutional Investors
11.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INZY FAQ
What was Inozyme Pharma, Inc.’s price range in the past 12 months?
Inozyme Pharma, Inc. lowest stock price was $1.32 and its highest was $7.79 in the past 12 months.
What is Inozyme Pharma, Inc.’s market cap?
Inozyme Pharma, Inc.’s market cap is $87.37M.
When is Inozyme Pharma, Inc.’s upcoming earnings report date?
Inozyme Pharma, Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 61 days.
How were Inozyme Pharma, Inc.’s earnings last quarter?
Inozyme Pharma, Inc. released its earnings results on Nov 05, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.435 by $0.045.
Is Inozyme Pharma, Inc. overvalued?
According to Wall Street analysts Inozyme Pharma, Inc.’s price is currently Undervalued.
Does Inozyme Pharma, Inc. pay dividends?
Inozyme Pharma, Inc. does not currently pay dividends.
What is Inozyme Pharma, Inc.’s EPS estimate?
Inozyme Pharma, Inc.’s EPS estimate is -0.41.
How many shares outstanding does Inozyme Pharma, Inc. have?
Inozyme Pharma, Inc. has 64,240,200 shares outstanding.
What happened to Inozyme Pharma, Inc.’s price movement after its last earnings report?
Inozyme Pharma, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.435. Following the earnings report the stock price went down -7.919%.
Which hedge fund is a major shareholder of Inozyme Pharma, Inc.?
Among the largest hedge funds holding Inozyme Pharma, Inc.’s share is Woodline Partners LP. It holds Inozyme Pharma, Inc.’s shares valued at 5M.
---
Inozyme Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (1297.06% Upside)
$19.00 (1297.06% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 9.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.14%
12-Months-Change
Fundamentals
Return on Equity
-79.42%
Trailing 12-Months
Asset Growth
-30.31%
Trailing 12-Months
Company Description
Inozyme Pharma, Inc.
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
---
INZY Stock 12 Month Forecast
Average Price Target
$19.00
▲(1297.06% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Kura Oncology
―
Cue Biopharma
―
X4 Pharmaceuticals
―
Bicycle Therapeutics
―
AnaptysBio
―
Best Analysts Covering INZY
1 Year
1 Year Success Rate
13/25 ratings generated profit
1 Year Average Return
+6.86%
reiterated a buy rating 8 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 52.00% of your transactions generating a profit, with an average return of +6.86% per trade.
---